MicroRNA‑708 inhibits the proliferation and invasion of osteosarcoma cells by directly targeting ZEB1 Retraction in /10.3892/mmr.2023.12936

He,Jun; Xiang,Deng; Lin,Yanshui

doi:10.3892/mmr.2019.10013

MicroRNA‑708 inhibits the proliferation and invasion of osteosarcoma cells by directly targeting ZEB1

Retraction in: /10.3892/mmr.2023.12936

Authors:
- Jun He
- Deng Xiang
- Yanshui Lin
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China
Published online on: March 6, 2019 https://doi.org/10.3892/mmr.2019.10013
Pages: 3948-3954

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous microRNAs (miRNAs) have been identified as aberrantly expressed in osteosarcoma (OS). miRNAs serve important roles in the pathogenesis of OS as oncogenes or tumor suppressors. Recent studies revealed that miR‑708‑5p (miR‑708) was dysregulated in various types of human cancer; however, its roles and underlying molecular mechanisms in OS remain unknown. Therefore, the present study aimed to determine miR‑708 expression in OS, investigate the roles of miR‑708 in the progression of OS and reveal the potential mechanisms involved. It was demonstrated using reverse transcription‑polymerase chain reaction that miR‑708 was downregulated in OS tissues and cell lines. Cell Counting Kit‑8 and Transwell assays revealed that miR‑708 overexpression suppressed the proliferation and invasion of OS cells in vitro. Additionally, zinc finger E‑box binding homeobox 1 (ZEB1) was validated as a direct target gene of miR‑708 in OS cells. ZEB1 was upregulated in OS tissues; elevated ZEB1 expression was negatively correlated with the levels of miR‑708 expression. Rescue experiments indicated that ZEB1 reintroduction significantly counteracted the inhibitory effects of miR‑708 overexpression on the proliferation and invasion of OS cells. The findings may improve understanding of the roles of miR‑708 in the development of OS, and suggest that miR‑708 may be a potential novel therapeutic target in the treatment of patients with this disease.

View Figures

View References

1	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
3	Bramer JA, van Linge JH, Grimer RJ and Scholten RJ: Prognostic factors in localized extremity osteosarcoma: A systematic review. Eur J Surg Oncol. 35:1030–1036. 2009. View Article : Google Scholar : PubMed/NCBI
4	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhou W, Hao M, Du X, Chen K, Wang G and Yang J: Advances in targeted therapy for osteosarcoma. Discov Med. 17:301–307. 2014.PubMed/NCBI
6	Tan ML, Choong PF and Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sun K and Lai EC: Adult-specific functions of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
10	Cai Y, Yu X, Hu S and Yu J: A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
11	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
12	Bracken CP, Scott HS and Goodall GJ: A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lin W, Zhu X, Yang S, Chen X, Wang L, Huang Z, Ding Y, Huang L and Lv C: MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2. Biomed Pharmacother. 91:1075–1084. 2017. View Article : Google Scholar : PubMed/NCBI
14	Jiang Z, Jiang C, Yu C and Fang J: MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. Tumour Biol. 39:10104283177057512017. View Article : Google Scholar : PubMed/NCBI
15	Wu X, Yan L, Liu Y, Xian W, Wang L and Ding X: MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7. PLoS One. 12:e01755532017. View Article : Google Scholar : PubMed/NCBI
16	Tian L, Guo Z, Wang H and Liu X: MicroRNA-635 inhibits the malignancy of osteosarcoma by inducing apoptosis. Mol Med Rep. 16:4829–4834. 2017. View Article : Google Scholar : PubMed/NCBI
17	Kim YH, Goh TS, Lee CS, Oh SO, Kim JI, Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma: A meta-analysis. Oncotarget. 8:8726–8737. 2017.PubMed/NCBI
18	Kushlinskii NE, Fridman MV and Braga EA: Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
19	Sampson VB, Yoo S, Kumar A, Vetter NS and Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
20	Li Q, Li S, Wu Y and Gao F: miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3. Oncol Lett. 14:2552–2558. 2017. View Article : Google Scholar : PubMed/NCBI
21	Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N and Milicevic M: Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 7:2274–2291. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li X, Zhong X, Pan X and Ji Y: Tumor suppressive microRNA-708 targets Notch1 to suppress cell proliferation and invasion in gastric cancer. Oncol Res. 2018.
23	Song XF, Wang QH and Huo R: Effects of microRNA-708 on epithelial-mesenchymal transition, cell proliferation and apoptosis in melanoma cells by targeting LEF1 through the Wnt signaling pathway. Pathol Oncol Res. 25:377–389. 2019. View Article : Google Scholar : PubMed/NCBI
24	Kim EA, Kim SW, Nam J, Sung EG, Song IH, Kim JY, Kwon TK and Lee TJ: Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget. 7:31832–31846. 2016.PubMed/NCBI
25	Delsin LEA, Roberto GM, Fedatto PF, Engel EE, Scrideli CA, Tone LG and Brassesco MS: Downregulated adhesion-associated microRNAs as prognostic predictors in childhood osteosarcoma. Pathol Oncol Res. 25:11–20. 2019. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Liu D, Zhang C, Li X, Zhang H, Pang Q and Wan A: MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma. EXCLI J. 17:102–112. 2018.PubMed/NCBI
28	Du L, Chen T, Zhao K and Yang D: miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression. Onco Targets Ther. 11:2195–2202. 2018. View Article : Google Scholar : PubMed/NCBI
29	Yao Q, Pei Y, Zhang X and Xie B: microRNA-96 acts as a tumor suppressor gene in human osteosarcoma via target regulation of EZRIN. Life Sci. 203:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
30	Guo P, Lan J, Ge J, Nie Q, Mao Q and Qiu Y: miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep. 30:870–876. 2013. View Article : Google Scholar : PubMed/NCBI
31	Lei SL, Zhao H, Yao HL, Chen Y, Lei ZD, Liu KJ and Yang Q: Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells. Oncol Lett. 8:1768–1774. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, et al: Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
33	Song T, Zhang X, Zhang L, Dong J, Cai W, Gao J and Hong B: miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol. 139:1189–1198. 2013. View Article : Google Scholar : PubMed/NCBI
34	Zhang Y, Li H, Cao R, Sun L, Wang Y, Fan S, Zhao Y, Kong D, Cui L, Lin L, et al: Suppression of miR-708 inhibits the Wnt/β-catenin signaling pathway by activating DKK3 in adult B-all. Oncotarget. 8:64114–64128. 2017.PubMed/NCBI
35	Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, Yin ZF and Yang JM: Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 19:1700–1706. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zhang Y, Liu G, Wu S, Jiang F, Xie J and Wang Y: Zinc finger E-box-binding homeobox 1: Its clinical significance and functional role in human thyroid cancer. Onco Targets Ther. 9:1303–1310. 2016.PubMed/NCBI
37	Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H and Cai J: MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1. Arch Biochem Biophys. 640:53–60. 2018. View Article : Google Scholar : PubMed/NCBI
38	Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et al: ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
39	Jia B, Liu H, Kong Q and Li B: Overexpression of ZEB1 associated with metastasis and invasion in patients with gastric carcinoma. Mol Cell Biochem. 366:223–229. 2012. View Article : Google Scholar : PubMed/NCBI
40	Shen A, Zhang Y, Yang H, Xu R and Huang G: Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
41	Liu C and Lin J: Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1. Am J Transl Res. 8:4095–4105. 2016.PubMed/NCBI
42	Xu J, Wang Z, Liao Z, Dai D and Ma X: MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma. Oncol Lett. 14:2483–2490. 2017. View Article : Google Scholar : PubMed/NCBI
43	Yan H, Zhang B, Fang C and Chen L: miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1. Anticancer Drugs. 29:440–448. 2018. View Article : Google Scholar : PubMed/NCBI
44	Wang H, Xing D, Ren D, Feng W, Chen Y, Zhao Z, Xiao Z and Peng Z: MicroRNA643 regulates the expression of ZEB1 and inhibits tumorigenesis in osteosarcoma. Mol Med Rep. 16:5157–5164. 2017. View Article : Google Scholar : PubMed/NCBI